Analyst Forecasts $101-117/Share Offer Price For Horizon Therapeutics' Buyout
Horizon Therapeutics Plc (NASDAQ: HZNP) confirmed it's engaged in preliminary talks with Amgen Inc (NASDAQ: AMGN), Janssen Global Service, and Sanofi SA SNY on potential takeover offers for the company.
SVB Leerink projects 2023 revenue of $4.0 billion, adj operating income of $1.6 billion, and EPS of $5.51.
Assuming no COGS nor R&D synergies but "fully synergized" SG&A of 21%, the company's theoretical 2023 fully synergized operating margin would be 54%, and adj EPS would be $7.79.
If an acquirer were to pay a low-mid teens (13-15x) multiple of SVB's estimate of fully-synergized adj EPS, it could yield a potential acquisition price of $101-117/share.
Valuation could be higher if an acquirer assumes faster long-term growth prospects or lower if an acquirer is concerned about the potential late-decade erosion of Tepezza following chronic market penetration and new thyroid eye disease competitive entrants.
For Johnson & Johnson (NYSE: JNJ), a deal would be on top of the recently-announced $16.6 billion acquisition of medical device firm Abiomed (NASDAQ: ABMD). Still, it would help partially offset the upcoming Stelara LOE impact on Pharma Immunology segment revenues.
For Sanofi, Horizon's assets could fit with the company's focus on I&I and Rare Diseases, but appetite is unclear.
For AMGN, Horizon's I&I and rare disease franchises would also fit. Horizon could help drive revenue & profit growth mid-late decade when Amgen faces generic and biosimilar pressures on key franchises.
Price Action: HZNP shares are up 26.9% at $99.94 on the last check Wednesday.
Latest Ratings for HZNP
Date | Firm | Action | From | To |
|---|---|---|---|---|
Mar 2022 | Morgan Stanley | Maintains | Overweight | |
Dec 2021 | Wells Fargo | Initiates Coverage On | Overweight | |
Nov 2021 | Goldman Sachs | Upgrades | Neutral | Buy |
View More Analyst Ratings for HZNP
View the Latest Analyst Ratings
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
